esanum is the medical platform on the Internet. Here, doctors have the opportunity to get in touch with a multitude of colleagues and to share interdisciplinary experiences. Discussions include both cases and observations from practice, as well as news and developments from everyday medical practice.
esanum ist die Ärzteplattform im Internet. Hier haben Ärzte die Möglichkeit, mit einer Vielzahl von Kollegen in Kontakt zu treten und interdisziplinär Erfahrungen auszutauschen. Diskussionen umfassen sowohl Fälle und Beobachtungen aus der Praxis, als auch Neuigkeiten und Entwicklungen aus dem medizinischen Alltag.
esanum est un réseau social pour les médecins. Rejoignez la communauté et partagez votre expérience avec vos confrères. Actualités santé, comptes-rendus d'études scientifiques et congrès médicaux : retrouvez toute l'actualité de votre spécialité médicale sur esanum.
Treatment with the IL17 inhibitor secukinumab inhibits radiographic progression in patients with psoriatic arthritis: this promising result could be shown in the large FUTURE 5 trial.
Prof. Philip J. Mease, (Swedish Medical Center and University of Washington, Seattle, USA) explained that secukinumab, a fully human monoclonal antibody, selectively neutralizes IL-17A. This has shown significant and rapid efficacy against psoriatic arthritis (PsA) in the FUTURE 5 I and II trials. In itself, FUTURE 5 is to date the largest randomized controlled trial of a biologic in PsA ever conducted, with nearly 1,000 patients studied. The trial assessed the efficacy of secukinumab to inhibit radiographic progression of structural damage as a secondary study endpoint.
During the 2017 American Congress of Rheumatology meeting, new data from this trial provided further evidence on the efficacy of secukinumab to reduce structural disease progression. Radiographic structural progression was measured by modified total van der Heijde Sharp Score (mTSS) and assessed by two blinded readers based on X-rays of the hand, wrist or foot. Radiographic progression was significantly inhibited at week 24 in all secukinumab arms (150 mg or 300 mg with or without loading dose) versus placebo. Patients treated with secukinumab also showed a dramatic improvement in enthesitis and dactylitis. ‘This means a lot for our patients. Enthesitis of the Achilles tendon is a major functional impairment’, said Prof. Mease.
Efficacy across all endpoints was greater in patients who were anti-TNF-naïve patients. In addition, patients treated with secukinumab showed up to 62% improvement in their responses at week 16 (primary study endpoint).
Mease PJ. Going Deeper With COSENTYX® (secukinumab) for Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) and Mease PJ, et al. Subcutaneous Secukinumab Inhibits Radiographic Progression in Psoriatic Arthritis: Primary Results from a Large Randomized, Controlled, Double-Blind Phase 3 Study. Abstract 17L, 2017 ACR/ARHP Annual Meeting, November 3-8 2017, San Diego (CA/USA).